FDA Lifts Clinical Hold on Tradipitant, Clearing Path for First New Motion Sickness Treatment in 40 Years
核心洞察
The FDA has lifted a partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness (搜索), removing the previous 90-dose limitation after determining motion sickness is an acute condition rather than chronic.
The decision eliminates the need for an additional six-month dog toxicity study and allows Vanda to extend clinical studies of the neurokinin-1 receptor (搜索) antagonist.
Tradipitant's New Drug Application remains on track for FDA review with a December 30, 2025 PDUFA date, potentially becoming the first new pharmacologic motion sickness (搜索) treatment in over four decades.
The U.S. Food and Drug Administration has lifted a partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness (搜索), removing regulatory barriers that could have delayed development of what may become the first new pharmacologic treatment for motion sickness in over 40 years.
The FDA announced its decision on December 4, 2025, following Vanda's formal dispute resolution request and an expedited re-review conducted by CDER leadership under a collaborative framework established between the company and the agency in October 2025. The partial clinical hold on protocol VP-VLY-686-3403 had previously limited the protocol to a maximum of 90 doses of tradipitant.
FDA Reclassifies Motion Sickness as Acute Condition
The regulatory breakthrough came after the FDA agreed with Vanda's position that motion sickness (搜索) represents an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition. This reclassification led the agency to conclude that tradipitant use in motion sickness constitutes an acute, event-driven therapy, eliminating the need for an additional six-month dog toxicity study that had prompted the original clinical hold.
"The swift and favorable resolution of this issue highlights the effectiveness of our collaborative framework with the FDA," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals. "We thank the Agency for its thorough and expedited scientific review and look forward to continued constructive dialogue."
NDA Review Remains on Track
The decision allows Vanda to extend clinical studies of tradipitant in motion sickness (搜索) while the company's New Drug Application for the prevention of vomiting (搜索) induced by motion remains under FDA review. The application maintains its PDUFA target action date of December 30, 2025, positioning tradipitant as potentially the first new pharmacologic treatment for motion sickness in over four decades.
About Tradipitant
Tradipitant is a neurokinin-1 receptor (搜索) antagonist that Vanda licensed from Eli Lilly and Company. The drug candidate is currently in clinical development for multiple indications beyond motion sickness (搜索), including gastroparesis (搜索) and the prevention of nausea (搜索) and vomiting (搜索) induced by GLP-1 receptor (搜索) agonists.
The regulatory milestone represents a significant step forward for addressing motion sickness (搜索), a condition that has seen limited therapeutic innovation in recent decades. The FDA's decision to lift the clinical hold demonstrates the potential for collaborative regulatory frameworks to expedite the development of treatments for unmet medical needs.